Compare Medtronic PLC (MDT) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Medtronic PLC trades at $83.21 (market cap $106.61B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.5. The key difference: Medtronic PLC pays a 3.46% dividend while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF pays none, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Medtronic PLC nearer its low. Which is the better fit depends on your goals.
| MDT | PDBC | |
|---|---|---|
Market Cap | $106.61B | — |
Sector | Health | — |
52-Week High | $105.35 | $18.91 |
52-Week Low | $73.75 | $12.90 |
Enterprise Value | $125.36B | — |
Dividend Yield | 3.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
PDBC trades at $17.38, up 0.75% with strong institutional interest as Geneos Wealth Management increased its position by 150.6% in Q1 2026. The ETF shows bullish technical signals with moving averages supporting upward momentum, though RSI levels indicate potential overbought conditions. PDBC has delivered 37% returns since March 2024, outperforming the S&P 500 by nearly 10 percentage points, driven by commodity price strength and Middle East supply disruptions.
Outlook remains positive given commodity momentum and inflation hedging demand, but risks include recent commodity weakness and the fund's complex tax structure. The ETF's annual distribution is unpredictable, swinging with commodity prices, which may disappoint income-focused investors despite strong total returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
